Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib + Nivolumab +/- Ipilimumab in Advanced Solid Tumors and Lymphoma
NCT03502733Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2018
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of copanlisib in lymphoma and solid tumor (3 cohorts), sponsored by National Cancer Institute. Primary endpoints: Recommended Phase 2 Dose at 28 days and Incidence of Adverse Events. Started Aug 2018; status: active, not recruiting.
02
Drugs
copanlisib
03
Conditions
lymphomasolid tumor
Beyond the preview
Go deeper on NCT03502733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502733.